JP5514810B2 - ピリドキシンに由来するｈｉｖインテグラーゼ阻害剤 - Google Patents

ピリドキシンに由来するｈｉｖインテグラーゼ阻害剤 Download PDF

Info

Publication number
JP5514810B2
JP5514810B2 JP2011511948A JP2011511948A JP5514810B2 JP 5514810 B2 JP5514810 B2 JP 5514810B2 JP 2011511948 A JP2011511948 A JP 2011511948A JP 2011511948 A JP2011511948 A JP 2011511948A JP 5514810 B2 JP5514810 B2 JP 5514810B2
Authority
JP
Japan
Prior art keywords
pyridine
hydroxymethyl
hydroxy
methyl
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011511948A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011521979A5 (enExample
JP2011521979A (ja
Inventor
ブレント ストラニクス
フランシス ボーリュー
ジャン−エマニュエル ブシャール
ガイ ミロ
ワン チーガン
レジャン リュエル
Original Assignee
タイメッド バイオロジクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by タイメッド バイオロジクス インコーポレイテッド filed Critical タイメッド バイオロジクス インコーポレイテッド
Publication of JP2011521979A publication Critical patent/JP2011521979A/ja
Publication of JP2011521979A5 publication Critical patent/JP2011521979A5/ja
Application granted granted Critical
Publication of JP5514810B2 publication Critical patent/JP5514810B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2011511948A 2008-06-04 2009-06-04 ピリドキシンに由来するｈｉｖインテグラーゼ阻害剤 Expired - Fee Related JP5514810B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13087408P 2008-06-04 2008-06-04
US61/130,874 2008-06-06
PCT/CA2009/000787 WO2009146555A1 (en) 2008-06-04 2009-06-04 Hiv integrase inhibitors from pyridoxine

Publications (3)

Publication Number Publication Date
JP2011521979A JP2011521979A (ja) 2011-07-28
JP2011521979A5 JP2011521979A5 (enExample) 2012-01-05
JP5514810B2 true JP5514810B2 (ja) 2014-06-04

Family

ID=41397686

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011511948A Expired - Fee Related JP5514810B2 (ja) 2008-06-04 2009-06-04 ピリドキシンに由来するｈｉｖインテグラーゼ阻害剤

Country Status (8)

Country Link
US (1) US8742123B2 (enExample)
EP (1) EP2300433A4 (enExample)
JP (1) JP5514810B2 (enExample)
CN (1) CN102112447B (enExample)
AU (1) AU2009253812A1 (enExample)
CA (1) CA2726742A1 (enExample)
RU (1) RU2010153656A (enExample)
WO (1) WO2009146555A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8410300B2 (en) 2006-09-21 2013-04-02 Taimed Biologics, Inc. Protease inhibitors
JP2010523476A (ja) 2007-03-08 2010-07-15 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ ミトコンドリアアルデヒドデヒドロゲナーゼ−２モジュレーター及びその使用方法
CN102209541B (zh) 2008-09-08 2016-05-18 小利兰·斯坦福大学托管委员会 醛脱氢酶活性调节剂和其使用方法
JP2012506856A (ja) 2008-10-28 2012-03-22 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アルデヒドデヒドロゲナーゼのモジュレーターおよびその使用方法
US8283366B2 (en) * 2010-01-22 2012-10-09 Ambrilia Biopharma, Inc. Derivatives of pyridoxine for inhibiting HIV integrase
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
WO2013102145A1 (en) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
JP6242810B2 (ja) 2011-12-28 2017-12-06 グローバル・ブラッド・セラピューティクス・インコーポレイテッドＧｌｏｂａｌ Ｂｌｏｏｄ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 置換ベンズアルデヒド化合物および組織酸素化の増加におけるそれらの使用方法
KR20150135332A (ko) * 2013-03-14 2015-12-02 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 미토콘드리아 알데히드 탈수소효소-2 조절인자들 및 이들의 사용 방법
SG11201507320QA (en) 2013-03-15 2015-10-29 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
ES2993155T3 (en) 2013-03-15 2024-12-23 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
SG11201507453VA (en) 2013-03-15 2015-10-29 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
PL3102208T5 (pl) 2014-02-07 2024-10-14 Global Blood Therapeutics, Inc. Krystaliczny polimorf wolnej zasady 2-hydroksy-6-((2-(1-izopropylo-1h-pirazol-5-ilo)pirydyn-3-ylo)metoksy)benzaldehydu
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
ES3039236T3 (en) 2015-12-04 2025-10-20 Global Blood Therapeutics Inc Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
TW202246215A (zh) 2015-12-18 2022-12-01 美商亞德利克斯公司 作為非全身ｔｇｒ５促效劑之經取代之４－苯基吡啶化合物
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
TWI752307B (zh) 2016-05-12 2022-01-11 美商全球血液治療公司 新穎化合物及製造化合物之方法
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
CN108203439B (zh) * 2016-12-20 2020-04-14 四川大学 苯乙烯吡啶类化合物、其制备方法和用途
RU2641309C1 (ru) * 2017-07-24 2018-01-17 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Антисептическое лекарственное средство
EP3687538B1 (en) * 2017-10-30 2024-04-17 Montreal Heart Institute Methods of treating elevated plasma cholesterol
US11014884B2 (en) 2018-10-01 2021-05-25 Global Blood Therapeutics, Inc. Modulators of hemoglobin
US12404260B2 (en) * 2019-04-11 2025-09-02 Janssen Pharmaceutica Nv Pyridine rings containing derivatives as MALT1 inhibitors
WO2020237374A1 (en) * 2019-05-28 2020-12-03 Montreal Heart Institute Picolinic acid derivatives and use thereof for treating diseases associated with elevated cholesterol
CN113116890B (zh) * 2021-04-25 2022-06-03 西南大学 5-Pyridoxolactone用于制备抑制家蚕核型多角体病毒的药物中的应用
CN117343006B (zh) * 2023-10-08 2024-07-09 河南科技大学 一种arb-272572的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107291A (en) 1997-12-19 2000-08-22 Amgen Inc. Azepine or larger medium ring derivatives and methods of use
ATE260255T1 (de) * 1998-11-05 2004-03-15 Pfizer Prod Inc 5-oxo-pyrrolidine-2-carbonsäure- hydroxamidderivate
PA8586801A1 (es) 2002-10-31 2005-02-04 Pfizer Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
EP1656348B1 (en) * 2003-08-20 2007-02-07 Axys Pharmaceuticals, Inc. Acetylene derivatives as inhibitors of histone deacetylase
CA2564356A1 (en) * 2004-04-26 2005-11-03 Pfizer Inc. Pyrrolopyridine derivatives and their use as hiv-integrase inhibitors
US8114886B2 (en) * 2005-04-08 2012-02-14 Daiichi Sankyo Company, Limited Pyridylmethylsulfone derivative

Also Published As

Publication number Publication date
WO2009146555A8 (en) 2010-12-23
US8742123B2 (en) 2014-06-03
EP2300433A1 (en) 2011-03-30
RU2010153656A (ru) 2012-07-20
EP2300433A4 (en) 2012-03-07
CA2726742A1 (en) 2009-12-10
AU2009253812A1 (en) 2009-12-10
CN102112447A (zh) 2011-06-29
WO2009146555A1 (en) 2009-12-10
CN102112447B (zh) 2013-06-26
US20110178120A1 (en) 2011-07-21
JP2011521979A (ja) 2011-07-28

Similar Documents

Publication Publication Date Title
JP5514810B2 (ja) ピリドキシンに由来するｈｉｖインテグラーゼ阻害剤
US12227488B2 (en) Small molecule degraders of Helios and methods of use
JP7654643B2 (ja) ホスホジエステラーゼ阻害剤および使用
US10358446B2 (en) Bruton's tyrosine kinase inhibitors
KR102320082B1 (ko) 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법
US12234220B2 (en) Immunomodulatory compounds
IL272649B2 (en) Ahr inhibitors and uses thereof
CN103012399B (zh) 7-氧代吡啶并嘧啶类化合物及其药用组合物和应用
WO1995028387A1 (en) Benzamide compound and medicinal use thereof
MXPA02003958A (es) Naftiridinas condensadas como inhibidores de la transcriptasa inversa del virus de inmunodeficiencia humana (vih).
EP1937639B1 (en) Pyridinaminosulfonyl substituted benzamides as inhibitors of cytochrome p450 3a4 (cyp3a4)
CN106794176A (zh) 色氨酸双加氧酶(ido1和tdo)的抑制剂和其在治疗中的用途
CN108530444B (zh) 一种新型nampt和ido双重抑制剂及其制备方法和医药用途
EP3290412A1 (en) Hiv-1 nucleocapsid inhibitors
SK75796A3 (en) Hiv protease inhibitors, pharmaceutical compositions containing them and their use
CA3172589A1 (en) Piperidine-2,6-diones as small molecule degraders of helios and methods of use
TW202229309A (zh) 用於冠狀病毒感染之治療之組合物及方法
JP2013517302A (ja) Ｈｉｖインテグラーゼを阻害するためのピリドキシン誘導体
US11673889B2 (en) Substituted imidazo[4,5-c][1,8]naphthyridines as phosphodiesterase inhibitors
US20250388562A1 (en) Small molecule degraders of helios and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111109

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20130213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130821

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130822

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140317

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140331

R150 Certificate of patent or registration of utility model

Ref document number: 5514810

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees